Orphan Synergy Europe - Pharma Aktie [WKN DE: A14QXP / ISIN: FR0012127173]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Orphan Synergy Europe - Pharma SA

23.06.17		OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi® in Advanced Lung Cancer (Businesswire)
14.06.17		OSE Immunotherapeutics Announces Results of 2017 Annual Meeting of Shareholders (Businesswire)
23.05.17		Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE's Interleukin Receptor 7 Antagonist (Businesswire)
24.01.17		OSE Immunotherapeutics Announces That the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Pivotal Phase 3 Clinical Trial of Tedopi® in Non-Small Cell Lung Cancer (Businesswire)
28.11.16		OSE Immunotherapeutics Appoints Dr. Frédérique Corallo, as Chief Medical Officer, Immunology (Businesswire)
17.11.16		OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology (Businesswire)
15.11.16		Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases (Businesswire)
15.11.16		Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases (Businesswire)
15.11.16		OSE Immunotherapeutics Awarded First Prize and "Listed Company" Prize as Part of 2016 Deloitte In Extenso Technology Fast 50 Ouest (Businesswire)
04.11.16		OSE Immunotherapeutics: Total Number of Voting Rights and Shares (Businesswire)
24.10.16		OSE Immunotherapeutics to Present at 2016 MedStart Up Days (Businesswire)
04.10.16		OSE Immunotherapeutics to Present the Preclinical Data of Its New Checkpoint Inhibitor Effi-DEM on SIRP-a/CD47 Strategic Pathway at the 2016 Immune Checkpoint Inhibitors Conference (Businesswire)
20.09.16		OSE Immunotherapeutics to Present Atalante 1, the Registration Clinical Trial of Tedopi®, Ongoing in the U.S. and in Europe, at the World Conference on Lung Cancer (WCLC) (Businesswire)
15.09.16		OSE Immunotherapeutics reinforces its Clinical Team with the Appointment of Iris Pauporté as Clinical Project Director (Businesswire)
08.09.16		OSE Immunotherapeutics Reports on First-Half 2016 Positive Financial Results Driven by Key Clinical Milestones (Businesswire)
06.09.16		OSE Immunotherapeutics: Total Number of Voting Rights and Shares (Businesswire)
30.08.16		OSE Immunotherapeutics Will Present at the Rodman & Renshaw 18th Annual Global Investment Conference in New York City, September 11-13, 2016 (Businesswire)
05.07.16		OSE Immunotherapeutics announces exercise of option within global license agreement with Janssen for further clinical development of FR104 and potential commercialisation in autoimmune diseases (Businesswire)
20.06.16		OSE Immunotherapeutics Presents Significant Preclinical Results for New Generation Checkpoint Inhibitor, Effi-DEM, at the International Conference (Businesswire)
09.06.16		OSE Immunotherapeutics: Publication of the 2015 Reference Document (Businesswire)
31.05.16		OSE Pharma and Effimune Shareholders Approve Merger to Create OSE Immunotherapeutics (Businesswire)
19.05.16		OSE Pharma and Effimune Announce the Launch of a Non-Interventional Study in Hepatocellular Carcinoma under a Private-Public Collaborative Program (Businesswire)
18.05.16		Dominique Costantini, Co-Founder of OSE Pharma, Invited to « Bpifrance Inno Génération » in Paris, May 25 & 26, 2016 (Businesswire)
12.05.16		OSE Pharma : Presentation of the Future Entity OSE Immunotherapeutics at the 2nd « Annual Immuno-Oncology: BD&L and Investment Forum » (Businesswire)
27.04.16		OSE Pharma SA: Availability of Preparatory Documents for the Combined General Meeting of May 31, 2016 (Businesswire)
15.04.16		OSE Pharma and Effimune Announce the Signing of the Merger Treaty to Create OSE Immunotherapeutics (Businesswire)
11.04.16		OSE Pharma: Fifth Country Opens Recruitment in the Global Pivotal Phase 3 Trial of the Immunotherapy Tedopi® with Initiation in Hungary (Businesswire)
04.04.16		OSE Pharma to Join Workshop (Businesswire)
29.03.16		OSE Pharma to attend the Small & Midcap Event in Paris on 11 & 12 April, 2016 (GlobeNewswire)
29.03.16		OSE Pharma to Attend the Small & Midcap Event in Paris on 11 & 12 April, 2016 (Businesswire)
21.03.16		OSE Pharma: 2015 Annual Results in Line with Forecasts, and Significant Clinical Advances (Businesswire)
24.02.16		OSE Pharma and Effimune Announce Proposed Merger to Create Significant Immunotherapy Player (Businesswire)
22.02.16		OSE Pharma SA: First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi® for advanced non-small cell lung cancer (Businesswire)
04.02.16		OSE Pharma Announces U.S. Initiation of Atalante 1, the Company’s Global, Pivotal Phase 3 Trial for Tedopi® Immunotherapy in Non-Small Cell Lung Cancer (Businesswire)
06.01.16		OSE Pharma Announces Initiation of Its Pivotal Phase 3 Trial of Tedopi® in Non-Small Cell Lung Cancer (Businesswire)
05.01.16		OSE Pharma Announces Its Events for Q1 2016 (Businesswire)
23.12.15		OSE Pharma Announces Selection of 70 International Clinical Centers to Participate in Its Pivotal Phase 3 Trial of Tedopi® for Patients Diagnosed with Advanced Non-Small Cell Lung Cancer (NSCLC) (Businesswire)
14.12.15		OSE Pharma to Participate to Biotech Showcase™ During JP Morgan Healthcare Conference (Businesswire)
07.12.15		OSE Pharma Admitted to Long-Only Deferred Settlement Service (Businesswire)
19.11.15		OSE Pharma Successfully Completes the Manufacturing of the Clinical Batches for Its Pivotal Phase 3 Clinical Trial with Tedopi® (Businesswire)
02.11.15		OSE Pharma receives positive opinion from several European countries to start pivotal Phase 3 trial of Tedopi® (Businesswire)
20.10.15		OSE Pharma to attend BIO-Europe 2015 (Businesswire)
29.09.15		OSE Pharma to participate to the Large & Midcap Event in Paris on October 7-8, 2015 (GlobeNewswire)
16.09.15		OSE Pharma Enters Euronext Index CAC® Small, CAC® Mid & Small and CAC® All-Tradable (Businesswire)
14.09.15		Ose Pharma to Attend BioPharm America September 15th to 16th, 2015, Boston, United-States (Businesswire)
10.09.15		OSE Pharma SA: Results for the First Half of 2015 in Line with Forecasts and Major Clinical Advances (Businesswire)
09.09.15		OSE PHARMA unveils Clinical and immunological outcomes in patients with brain metastases treated with Tedopi® in a phase 2 trial presented at the World Conference on Lung Cancer (WCLC) in Denver, USA (Businesswire)
01.09.15		OSE Pharma Sets up Scientific Steering Committee and Takes a First Step in the Launch of Its Phase 3 Trial in Lung Cancer (Businesswire)
23.07.15		OSE Pharma SA : Presentation of Tedopi’s Clinical Trial Data for Patients with Brain Metastasis Treated Due to Lung Cancer at the 16th World Conference on Lung Cancer (Businesswire)
15.06.15		OSE Pharma to attend "French Life Science Days” June 17th to 18th 2015, New York (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Neuer Rekord nicht mehr weit: Bitcoin, Ethereum, Litecoin & Co.: Wie sich die Kryptokurse am Mittag entwickeln

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

Krypto-Update: Diese fünf Kryptowährungen stehen derzeit im Fokus

Bitcoin überholt Silber: Kryptowährung auf Rekordkurs

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

Diese Aktien empfehlen Experten zu kaufen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	25.11.2024 20:30
Kaufwert:	EUR
	Hinzufügen Speichern